Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer

NCT06973421 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Platinum Resistant Ovarian Cancer

Interventions

DRUG: Utidelone Capsules
DRUG: Fruquintinib Capsules

Sponsor

Fudan University